ReviewCancers2021
Modern Diagnosis of Early Esophageal Cancer: From Blood Biomarkers to Advanced Endoscopy and Artificial Intelligence.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Efficacy and safety of tislelizumab in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis.Journal of the Egyptian National Cancer Institute · 2025Pooled it
- First-line benmelstobart plus anlotinib and chemotherapy in advanced or metastatic/recurrent esophageal squamous cell carcinoma: a multi-center phase 2 study.Signal transduction and targeted therapy · 2024Trial
- Early esophageal cancer diagnosis in Central Oromia, Ethiopia: patient and provider perspectives on barriers and facilitators.Scientific reports · 2026Article
- Systemic Inflammation Response Index, Albumin, and Hemoglobin-Albumin-Lymphocyte-Platelet Score for Stage-Stratified Esophageal Cancer Discrimination: A Retrospective Case-Control Study.Cancer management and research · 2026Article
- A TROP2-targeting ADC synergizes with oxidative phosphorylation inhibitor to enhance apoptosis in ESCC by suppressing the PI3K-AKT-mTOR signaling pathway.Cell death & disease · 2025Article
- The Interplay Between Esophageal Adenocarcinoma and Its Tumor Microenvironment: Toward Innovative Therapies.Cells · 2025Review
- Risk factors of fever following endoscopic radiofrequency ablation for early esophageal squamous cell carcinoma and precancerous lesions.World journal of gastrointestinal surgery · 2025Article
- Article
- A Clinical Validation of a Diagnostic Test for Esophageal Adenocarcinoma Based on a Novel Serum Glycoprotein Biomarker Panel: PromarkerEso.Proteomes · 2025Article
- Article
- A-to-I-Edited miR-1304-3p Inhibits Glycolysis and Tumor Growth of Esophageal Squamous Cell Carcinoma by Inactivating Wnt5a/ROR2 Signaling.Molecular carcinogenesis · 2025Article
- Locally advanced and metastatic esophageal squamous cell carcinoma in Morocco: from diagnosis to treatment.Ecancermedicalscience · 2025Article
- Development and external validation of a nomogram for predicting the risk of developing esophageal cancer based on a questionnaire: a multicenter case-control study.Frontiers in oncology · 2025Article
- Esophageal and Gastric Cancer Incidence and Mortality Trends in Norway, 1993-2022: A Registry-Based Study.Clinical epidemiology · 2025Article
- Pan-immune-inflammation value as a novel predictor of pathological response to neoadjuvant chemotherapy combined with anti-PD-1 therapy in esophageal squamous cell carcinoma: a multicenter real-world retrospective clinical study.Therapeutic advances in medical oncology · 2025Article
- Identification and Characterization of Prognostic Macrophage Subpopulations for Human Esophageal Carcinoma.Current medicinal chemistry · 2025Article
- Optical Methods for Optimizing Fluorescence Imaging Field of View and Image Quality in Surgical Guidance Procedures.Diagnostics (Basel, Switzerland) · 2024Article
- Article
- Novel milestones for early esophageal carcinoma: From bench to bed.World journal of gastrointestinal oncology · 2024Article
- Cysteine protease inhibitor 1 promotes metastasis by mediating an oxidative phosphorylation/MEK/ERK axis in esophageal squamous carcinoma cancer.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal cancer (EC) is the seventh most common cancer and the sixth cause of cancer death worldwide. Histologically, esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) account for up to 90% and 20% of all ECs, respectively. Clinical symptoms such as dysphagia, odynophagia, and bolus impaction occur late in the natural history of the disease, and the diagnosis is often delayed. The prognosis of ESCC and EAC is poor in advanced stages, being survival rates less than 20% at five years. However, when the diagnosis is achieved early, curative treatment is possible, and survival exceeds 80%. For these reasons, mass screening strategies for EC are highly desirable, and several options are currently under investigation. Blood biomarkers offer an inexpensive, non-invasive screening strategy for cancers, and novel technologies have allowed the identification of candidate markers for EC. The esophagus is easily accessible via endoscopy, and endoscopic imaging represents the gold standard for cancer surveillance. However, lesion recognition during endoscopic procedures is hampered by interobserver variability. To fill this gap, artificial intelligence (AI) has recently been explored and provided encouraging results. In this review, we provide a summary of currently available options to achieve early diagnosis of EC, focusing on blood biomarkers, advanced endoscopy, and AI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.